Journal
ACTA CARDIOLOGICA
Volume 77, Issue 7, Pages 632-638Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00015385.2021.1973770
Keywords
Ticagrelor; clopidogrel; acute coronary syndrome; systemic immune-inflammation index
Categories
Ask authors/readers for more resources
In this study, it was found that inflammatory parameters, including NLR, MHR, PLR, and SII, were significantly lower in ACS patients treated with ticagrelor compared to clopidogrel. This suggests that ticagrelor may have a positive impact on inflammatory response in PCI-treated ACS patients.
Objective Inflammation plays a critical role in atherosclerosis. This study examines the effects of ticagrelor and clopidogrel on inflammatory parameters, obtained from complete blood count (CBC) and biochemical measurements, in patients with acute coronary syndrome. Methods and Results One hundred acute coronary syndrome (ACS) patients were included in the study and grouped according to clopidogrel (n = 50) or ticagrelor (n = 50) usage as an anti-aggregant (with acetylsalicylic acid). All patients underwent percutaneous coronary intervention. On admission, at third- and sixth-month after ACS, white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-high-density lipoprotein ratio (MHR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated from the CBC and biochemical measurements. NLR, PLR, and SII were significantly lower in the ticagrelor group (p < 0.001, at 3rd and 6th month). Also, MHR was lower in the ticagrelor group (p < 0.05). Conversely, WBC count was higher in the ticagrelor group (p < 0.001). Conclusions NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available